More than 80 percent of clinical drug trials in Canada are funded by the pharmaceutical industry. This article evaluates the overall state of clinical trials in Canada and looks at the interplay between public and private interests. Health Canada has adopted standards developed by the International Conference on Harmonization, a body that is heavily influenced by industry. Commercial interests are increasingly involved in recruiting patients into clinical trials and in running these trials. It is in industry's interests to conduct drug tests on people for which it is easiest to see benefits. These interests are not fundamentally challenged by Health Canada's policy of issuing nonmandatory guidelines on who should and should not be included in clinical trials. The outcome of clinical trials is heavily influenced by commercial sponsorship, with the result that trials may favor corporate interests rather than the interests of the public. How Health Canada deals with that possibility is not known, because of its strict policy of treating clinical trial data as private property. If clinical trials are to serve the purpose for which they are designed, developing reliable and objective information about new drugs, then commercial interests cannot be allowed to take precedence over health interests.
SilversidesA.The tribulations of community-based trials. CMAJ170:33, 2004.
3.
Patented Medicine Prices Review Board. Annual Report 2001. Ottawa, 2002.
4.
Patented Medicine Prices Review Board. Annual Report 2003. Ottawa, 2004.
5.
Patented Medicine Prices Review Board. Annual Report 2005. Ottawa, 2006.
6.
Health Products and Food Branch. Review of the 2001 Clinical Trials Regulatory Framework: Part C, Division 5 of the Food and Drug Regulations (Drugs for Clinical Trials Involving Human Subjects). Health Canada, Ottawa, 2007.
Bégin, M., et al. Accelerating Access for Patients to Best Medicine: The System and the Challenge.Centre on Governance and Institute of Population Health, University of Ottawa, Ottawa, 2002.
WardaJ.Measuring the Attractiveness of R&D Tax Incentives: Canada and Major Industrial Countries. A report prepared for Foreign Affairs and International Trade Canada, Ontario Investment Service, and Statistics Canada. Statistics Canada, Ottawa, 1999.
KarleffI.Canada may speed access to its human guinea pigs: Ethicists queasy about plan to approve clinical trials in 48 hours. Globe and Mail (Toronto), October 25, 1999.
14.
Government of Canada. Regulations amending the Food and Drug Regulations (1024—clinical trials). Canada Gazette135:1116–1153, 2001.
15.
Auditor General of Canada. Allocating funds to regulatory programs—Health Canada? In Report of the Auditor General of Canada to the House of Commons, chap. 8. Ottawa, 2006.
16.
Therapeutic Products Programme. International Strategy. Ottawa, April 1999.
17.
AbrahamJ., and ReedT.Managing Knowledge and Expertise in Innovative Drug Testing.Economic and Social Research Council, Swindon, 1998.
18.
AbrahamJ., and ReedT.Trading risks for markets: The international harmonisation of pharmaceuticals regulation. Health Risk Society3:113–128, 2001.
19.
Standing Senate Committee on Social Affairs Science and Technology. The Health of Canadians—The Federal Role, Vol. 5: Principles and Recommendations for Reform—Part 1.The Senate, Ottawa, 2002.
LemmensT., and MillerP. B.The human subjects trade: Ethical and legal issues surrounding recruitment incentives. J. Law Med. Ethics31:398–418, 2003.
22.
BeaganB. L.Section E-1: Ethics review for human subjects research—interviews with members of research ethics boards and national organizations. In The Governance of Health Research Involving Human Subjects (HRIHS), ed. McDonaldM.. Law Commission of Canada, 2000.
23.
MunroM.Doctors buying ethics approval. Vancouver Sun, February 27, 2004.
24.
LemmensT., and FreedmanB.Ethics review for sale? Conflict of interest and commercial research review boards. Milbank Q.78:547–584, 2000.
25.
Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.Interagency Secretariat on Research Ethics, Ottawa, 2005.
26.
MunroM.UBC broke federal ethics rules by failing to adequately warn patients. Vancouver Sun, February 25, 2004.
27.
WaltersJ.Prozac research targets local girls. Hamilton Spectator, November 2, 2001.
28.
MunroM.Critical patients not informed UBC trial could hasten death: U.S. health officials. Vancouver Sun, February 27, 2004.
29.
MunroM.Doctors pressure human guinea pigs. Vancouver Sun, February 23, 2004.
30.
CornacchiaC.Cozying up to drug firms disturbs some physicians. Montreal Gazette, February 24, 2004.
31.
WalkerR.Why FP research works. Medical Post, August 10, 1999, p. 31.
32.
MunroM.Drug firms pay $3,000 or more per patient for trials. Vancouver Sun, February 24, 2004.
33.
LippmanA.The Inclusion of Women in Clinical Trials: Are We Asking the Right Questions?Women and Health Protection, Toronto, 2006.
34.
RochonP. A.BergerP. B., and GordonM.The evolution of clinical trials: Inclusion and representation. CMAJ159:1373–1374, 1998.
35.
CaronJ.Report on Governmental Health Research Policies Promoting Gender or Sex Differences Sensitivity.Institute of Gender and Health, Ottawa, 2003.
36.
Health Products and Food Branch. Guidance for Industry: Clinical Investigation of Medicinal Products in the Pediatric Population: ICH Topic E11.Health Canada, Ottawa, 2003.
37.
MunroM.“You failed to protect rights, safety and welfare” of boy. Vancouver Sun, February 26, 2004.
Health Canada. To Clinical Trial Sponsors: Requirements for Tuberculosis Screening of Healthy Volunteers in Phase I Clinical Trials Involving Immunosuppressant Drugs or Drugs with Immunosuppressant Properties. Ottawa, July 23, 2006.
40.
Health Products and Food Branch. Summary Report of the Inspections of Clinical Trials Conducted in 2003/2004.Health Canada, Ottawa, 2004.
41.
KesslerD. A.Therapeutic-class wars—drug promotion in a competitive marketplace. N. Engl. J. Med.331:1350–1353, 1994.
42.
MirowskiP., and Van HornR.The contract research organization and the commercialization of scientific research. Soc. Stud. Sci.35:503–548, 2005.
43.
RochonP. A.Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. CMAJ159:321–327, 1998.
44.
MelloM. M.ClarridgeB. R., and StuddertD. M.Academic medical centers' standards for clinical-trial agreements with industry. N. Engl. J. Med.352:2202–2210, 2005.
45.
Naylor, C. D., and Research Committee and Clinical Study Agreements Working Group of the Toronto Academic Health Science Council. Early Toronto experience with new standards for industry-sponsored clinical research—a progress report. CMAJ166:453–456, 2002.
46.
LexchinJ., and MintzesB.Transparency in drug regulation: Mirage or oasis?CMAJ171:1363–1365, 2004.
47.
Health Canada. Issue Analysis Summary: Summary Basis of Decision—Draft 7. Ottawa, 2004.
48.
KondroW., and SibbaldB.Drug company experts advised staff to withhold data about SSRI use in children. CMAJ170:783, 2004.
49.
MathewsA. W., and MartinezB.Warning signs: E-mails suggest Merck knew Vioxx's dangers at early stage as heart-risk evidence rose, officials played hardball; internal message: “dodge!”Wall Street Journal, November 1, 2004.
50.
MeierB.Merck backs U.S. database to track drug trials. New York Times, June 18, 2004.
51.
ZarinD. A.TseT., and IdeN. C.Trial registration at clinicaltrials.gov between May and October 2005. N. Engl. J. Med.353:2779–2787, 2005.
External Working Group on the Registration and Disclosure of Clinical Trial Information (EWG-CT). Final Report: Options for Improving Public Access to Information on Clinical Trials of Health Problems in Canada.Health Canada, Ottawa, 2006.
LexchinJ.Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: A hypothesis-generating study. Ann. Pharmacotherapy40:2216–2222, 2006.
56.
LawsonG. W.Impact of User Fees (i.e. Drug Industry Fees) on Changes within the FDA. 2005. www.fdastudy.com (January 19, 2008).
57.
Therapeutic Products Directorate. Business Transformation Progress Report.Health Canada, Ottawa, undated.
58.
Government of Canada. The Canada We Want: Speech from the Throne to Open the Second Session of the Thirty-Seventh Parliament of Canada. Ottawa, 2003.
59.
GrahamJ.Smart regulation: Will the government's strategy work?CMAJ173: 1469–1470, 2005.
